Browsing Tag
Pancreatic Cancer
32 posts
Can an A3 adenosine receptor agonist change the treatment ceiling in advanced pancreatic cancer
Can Can-Fite BioPharma Ltd.’s namodenoson change pancreatic cancer outcomes? Explore what its Phase 2a data means for investors and oncology strategy.
Vector Science & Therapeutics (TSXV: PAIN) targets intratumoral pancreatic cancer drug delivery with new microneedle catheter patent
Pancreatic cancer needs better local therapy. Vector Science & Therapeutics is betting its patent strategy can open a new delivery path.
Why pancreatic cancer clinicians and investors are closely watching AIM ImmunoTech’s next move
AIM ImmunoTech’s next Ampligen move could reshape pancreatic cancer treatment and investor sentiment. Find out what executives and markets are watching now.
Is elraglusib emerging as a new frontline option in metastatic PDAC?
Read how Actuate Therapeutics’ elraglusib Phase 2 survival data could reshape metastatic PDAC treatment and investor expectations.
Amplia Therapeutics (ASX:ATX) reports five complete responses and improved survival in ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) posts 7.8% complete response rate and 11.1-month mOS in ACCENT pancreatic cancer trial. Read the full strategic analysis.
Avacta (AIM: AVCT) opens AVA6103 Phase 1: Can sustained-release engineering salvage exatecan’s clinical legacy?
Avacta Therapeutics opens Phase 1 enrollment for AVA6103 exatecan PDC at two US oncology centers. Early data expected H2 2026. Read what it means for AVCT investors.
Could a proenzyme therapy disrupt chemotherapy’s dominance in pancreatic cancer treatment?
Can Propanc Biopharma’s PRP therapy reshape pancreatic cancer treatment? Discover what the biotech’s metastasis-focused strategy could mean for oncology.
How orphan drug status and patent protection shape Ampligen’s commercial and regulatory outlook
Discover how orphan drug status and long-dated patents could shape Ampligen’s regulatory path and commercial value in pancreatic cancer.
How a proenzyme-based approach from Propanc Biopharma tests the limits of current solid tumor paradigms
Can a proenzyme therapy reshape solid tumor treatment models? Explore what Propanc Biopharma’s PRP strategy signals for oncology markets.
Can Partner Therapeutics’ zenocutuzumab-zbco deliver a first-line breakthrough in NRG1+ lung cancer?
Zenocutuzumab-zbco by Partner Therapeutics shows durable first-line response in NRG1+ NSCLC. Find out what the new eNRGy trial data means for patients.